Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/26/12 → 6/4/14 |
Funding
- Tibotec Pharmaceuticals Ltd. (Protocol TMC435HPC2002)
Protocol TMC435HPC2002:An exploratory Phase IIa, randomized, open-label trial to investigate the efficacy and safety of 12 weeks or 24 weeks of TMC435 in combination with PSI-7977 with or without ribavirin in chronic hepatitis C genotype 1-infected prior
- Flamm, Steven L (PD/PI)
- Ganger, Daniel R (Co-Investigator)
Project: Research project